A Phase 3, Randomized, Double-blind Clinical Study to Evaluate the Long-term Safety and Efficacy of MK-7264 in Japanese Adult Participants With Refractory or Unexplained Chronic Cough
Phase of Trial: Phase III
Latest Information Update: 09 Jan 2019
At a glance
- Drugs Gefapixant (Primary)
- Indications Cough
- Focus Adverse reactions; Registrational
- Sponsors Merck Sharp & Dohme
- 12 Nov 2018 Planned primary completion date changed from 1 Oct 2020 to 6 Oct 2020.
- 12 Nov 2018 Status changed from not yet recruiting to recruiting.
- 11 Oct 2018 New trial record